drugset / Trial / NCT05265650
Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC
Phase 1/2
Unknown
30 enrolled
Clinica Universidad de Navarra, Universidad de Navarra
Highlight Therapeutics · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a study of repeated IT administrations of BO-112 in combination with ablative radiotherapy (SABR) and concurrent nivolumab in patients with metastatic PD-1/PD-L1-refractory NSCLC.
Timeline
- Start
- 2022-06-13
- Primary completion
- 2024-03
- Completion
- 2024-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BO-112 | Oligonucleotide (other) | 1 mg | Other |
| Subject | BO-112 | Oligonucleotide (other) | 2 mg | Other |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |